CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in HER2-mutated metastatic non-small cell...
Phase 2
Taipei City, Taiwan and 47 other locations
with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non- ...
Phase 2
Taipei, Taiwan and 64 other locations
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell...
Phase 2
Taipei City, Taiwan and 83 other locations
, HER3-DXd will be evaluated in participants with metastatic or unresectable NSCLC with EGFR activating mutation or squamous or non-squamous...
Phase 1
Taipei, Taiwan and 21 other locations
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...
Phase 2
Taipei, Taiwan and 23 other locations
in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with o...
Phase 3
Taipei, Taiwan and 205 other locations
type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer...
Phase 1, Phase 2
Taipei, Taiwan and 123 other locations
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell...
Phase 2
Taoyuan City, Taiwan and 29 other locations
This is a phase 3 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) compared to pembrolizumab in front-line, PD-L1-high, loca...
Phase 3
Taipei, Taiwan and 170 other locations
in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer...
Phase 3
Taipei, Taiwan and 139 other locations
Clinical trials
Research sites
Resources
Legal